These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 37341584)

  • 1. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
    Carvajal SK; Melendres J; Escandón P; Firacative C
    Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino acid substitution in Cryptococcus neoformans lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates.
    Bosco-Borgeat ME; Mazza M; Taverna CG; Córdoba S; Murisengo OA; Vivot W; Davel G
    Rev Argent Microbiol; 2016; 48(2):137-42. PubMed ID: 27311753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.
    Sionov E; Chang YC; Garraffo HM; Dolan MA; Ghannoum MA; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1162-9. PubMed ID: 22155829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.
    Gast CE; Basso LR; Bruzual I; Wong B
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5478-85. PubMed ID: 23979758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-azole-resistant strains of Cryptococcus neoformans var. grubii isolated from a FLZ-resistant strain by culturing in medium containing voriconazole.
    Kano R; Okubo M; Hasegawa A; Kamata H
    Med Mycol; 2017 Nov; 55(8):877-882. PubMed ID: 28927230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Isolation of Azole-Resistant Cryptococcus neoformans from Feline Cryptococcosis.
    Kano R; Okubo M; Yanai T; Hasegawa A; Kamata H
    Mycopathologia; 2015 Dec; 180(5-6):427-33. PubMed ID: 26162642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
    Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
    Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
    Chong HS; Dagg R; Malik R; Chen S; Carter D
    J Clin Microbiol; 2010 Nov; 48(11):4115-20. PubMed ID: 20844209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
    Basso LR; Gast CE; Bruzual I; Wong B
    J Antimicrob Chemother; 2015 May; 70(5):1396-407. PubMed ID: 25630649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal susceptibility of the clinical and environmental strains of Cryptococcus gattii sensu lato in Taiwan.
    Lin KH; Lai YC; Lin YP; Ho MW; Chen YC; Chung WH
    Mycoses; 2023 Jan; 66(1):13-24. PubMed ID: 35986599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
    Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
    Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal susceptibility of clinical Cryptococcus gattii isolates from Colombia varies among molecular types.
    Firacative C; Escandón P
    Med Mycol; 2021 Nov; 59(11):1122-1125. PubMed ID: 34264298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
    Bastos RW; Carneiro HCS; Oliveira LVN; Rocha KM; Freitas GJC; Costa MC; Magalhães TFF; Carvalho VSD; Rocha CE; Ferreira GF; Paixão TA; Moyrand F; Janbon G; Santos DA
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109169
    [No Abstract]   [Full Text] [Related]  

  • 18. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cloning of the lanosterol 14-α-demethylase ( ERG11 ) gene in Trichosporon asahii: a possible association between G453R amino acid substitution and azole resistance in T. asahii.
    Kushima H; Tokimatsu I; Ishii H; Kawano R; Shirai R; Kishi K; Hiramatsu K; Kadota J
    FEMS Yeast Res; 2012 Sep; 12(6):662-7. PubMed ID: 22621704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A New Amino Acid Substitution at G150S in Lanosterol 14-α Demethylase (Erg11 protein) in Multi-azole-resistant Trichosporon asahii.
    Kushima H; Tokimatsu I; Ishii H; Kawano R; Watanabe K; Kadota JI
    Med Mycol J; 2017; 58(1):E23-E28. PubMed ID: 28250360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.